Benefits
82% less insulin response than maltodextrin
Clinical testing confirmed Carb10® produces 82% less insulin response and 27% lower blood glucose peak vs. maltodextrin at equivalent carbohydrate doses. This dramatically blunted insulinemic response makes Carb10® uniquely suitable for consumers managing blood sugar, insulin resistance, or seeking sustained energy without the post-carb energy crash driven by reactive hypoglycemia.
Sustained workout energy without GI distress
Carb10's pea starch molecular structure provides a moderate digestion rate that sustains glucose delivery over 2–3 hours — longer than high-GI carbs but without the bloating and GI discomfort associated with fiber-heavy or slowly-digested carbs. Well-tolerated as a pre/intra-workout fuel for sustained performance.
Insulin-sensitive and low-carb compatible fueling
For individuals managing metabolic conditions, following low-glycemic diets, or using time-restricted eating protocols, Carb10® provides carbohydrate energy without the insulin and glucose disruption that can impair metabolic health goals. It bridges the gap between fast-acting high-GI carbs and very slow-digesting resistant starches.
Mechanism of action
Pea starch digestion kinetics and low GI response
Carb10®'s pea starch structure (high amylose content relative to other starches) slows amylase-mediated digestion, releasing glucose more gradually into the bloodstream. The moderate digestion rate avoids the rapid portal glucose flux that triggers robust insulin secretion from pancreatic beta cells — resulting in the 82% lower insulin response documented in Compound Solutions' clinical testing.
Clinical trials
Manufacturer-published comparative clinical study examining blood glucose and insulin response to Carb10® (pea-derived starch) vs equivalent dose of maltodextrin in healthy subjects. Acute postprandial design.
Manufacturer-funded testing comparing Carb10® (proprietary pea starch from Compound Solutions) to maltodextrin in healthy adults for glycemic and insulin response. Study details and methodology have not been published in a peer-reviewed PubMed-indexed journal. Findings reported on Compound Solutions product literature.
Manufacturer-reported: Carb10® demonstrated 82% lower insulin response and 27% lower blood glucose response compared to maltodextrin in head-to-head testing. Pea starch is a slowly-digested resistant carbohydrate with prebiotic properties and low osmolality (reducing GI distress vs maltodextrin). NOTE: This data has not been published in a PubMed-indexed peer-reviewed journal as of May 2026. The closest PubMed-indexed evidence supporting low-glycemic pea starch effects is general literature on resistant starch glycemic response. Recommend formulators wait for independent peer-reviewed publication for confidence.